EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
FDA rejects Alnylam's heart disease treatment over insufficient data
Next article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Moonlake's readout produced a cash windfall. Risks remain
